Site Map
PATIENTS
PATIENTS SJIA - PATIENTSHow ACTEMRA Works
Is Actemra Right For You
Patient Stories
Clinical Trials
Taking ACTEMRA
What To Expect
ACTEMRA Dosing
Assessing Response to Treatment
Talking to Your Rheumatologist
Understanding Your Test Results
Setting Goals for Treatment
Your RA Team
RA Profiler
Talking About RA
Information for Caregivers
Paying for ACTEMRA
Appointment Calendar
Recipes
Exercises
Polls
Resources
SJIA - PATIENTS
What to Expect
How ACTEMRA Works
How ACTEMRA is Given
Preparing for Treatment
Diagnosing SJIA
Treating SJIA
Glossary
Paying for ACTEMRA
HEALTHCARE PROFESSIONALS
HEALTHCARE PROFESSIONALS SJIA - HEALTHCARE PROFESSIONALSPatient Types
Clinical Response
ACTEMRA Monotherapy
Safety Profile
ACTEMRA Monitoring
Video Library
Pharmacodynamics
Dosing Calculator
Coverage & Payment
SJIA - HEALTHCARE PROFESSIONALS
ACR Response
Articular Improvements
Systemic Improvements
Steroid Use Reduction
Laboratory Tests
Dosing Calculator
Coverage & Payment
ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
IMPORTANT SAFETY INFORMATION
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.
ACTEMRA should not be administered to patients with known hypersensitivity to ACTEMRA.
- If anaphylaxis or other clinically significant hypersensitivity reaction occurs, administration of ACTEMRA should be stopped immediately and ACTEMRA should be permanently discontinued.
Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations and hypersensitivity reactions. Other potential risks of ACTEMRA include demyelinating disorders and malignancies.
Common adverse reactions include upper respiratory infection, nasopharyngitis, headache, hypertension, and increased ALT.
Please see full Prescribing Information, including Boxed Warning for additional important safety information.
The resource above is provided in Adobe® Reader® format (PDF). To view or print, you must have Adobe Reader (version 3.0 or higher) installed on your computer. Download the free Adobe Reader here.
This information does not take the place of talking to your child's healthcare provider about either your child's medical condition or your child's treatment with ACTEMRA. Talk with your child's healthcare provider if you have any questions about your child's treatment with ACTEMRA.
What is ACTEMRA?
ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor inhibitor. ACTEMRA is used to treat patients with active systemic juvenile idiopathic arthritis (SJIA) 2 years of age and older.
IMPORTANT SIDE EFFECT INFORMATION
Some people have serious infections while taking ACTEMRA, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.
Other serious side effects of ACTEMRA include tears (perforation) of the stomach and intestines, changes in blood test results, (including low neutrophil count, low platelet count, increase in certain liver function tests, and increase in blood cholesterol levels), hepatitis B infection becoming an active infection again, and nervous system problems.
ACTEMRA affects the immune system and may increase your risk of certain cancers.
Serious allergic reactions, including death, can happen with ACTEMRA. These reactions may happen with any infusion of ACTEMRA, even if they did not occur with an earlier infusion. Patients must tell their doctor if they have had a previous reaction to ACTEMRA. Patients should not take ACTEMRA if they are allergic to it or any of its ingredients.
Common side effects with ACTEMRA in patients with SJIA include upper respiratory tract infections (common cold, sinus infections), headache, and diarrhea.
Patients must tell their healthcare provider if they plan to become pregnant or are pregnant. It is not known if ACTEMRA will harm an unborn baby. Genentech has a registry for pregnant women who take ACTEMRA. Patients who are pregnant or become pregnant while taking ACTEMRA must contact the registry at 1-877-311-8972 and talk to their healthcare provider.
Patients must call their healthcare provider for medical advice about any side effects. Patients or caregivers may report side effects to the FDA at 1-800-FDA-1088. Patients or caregivers may also report side effects to Genentech at 1-888-835-2555.
For additional important safety information, including Boxed Warning and Medication Guide, please visit ACTEMRA.com or call (800) ACTEMRA (800-228-3672).
The resource above is provided in Adobe® Reader® format (PDF). To view or print, you must have Adobe Reader (version 3.0 or higher) installed on your computer. Download the free Adobe Reader here.
